Video: Can Fasting Make Chemotherapy Work BETTER? What Clinical Trials Show

What if skipping a few meals around your chemotherapy infusion could help the treatment work better and make you feel less sick while it's working? It sounds almost too simple, but a growing stack of clinical trials, including a major study just presented in 2026, says it might be true. Hey everybody, great to be with you. Let's talk about fasting before chemotherapy, what the latest research shows. For decades, cancer treatment research has focused almost entirely on which drugs to use and at what dose. But a newer question is gaining traction. Does what a patient eats or doesn't eat around the time of chemo change how well that chemo actually works? In this video, we'll cover the science behind fasting and chemotherapy, how these fasting protocols actually work, the key studies behind the headlines, and what's still uncertain. So, why would simply not eating affect how chemo works? The concept researchers use is called differential stress resistance. Here's the idea in plain terms. When you stop eating for a period of time, your healthy cells sense that nutrients are scarce. In response, they essentially hit the brakes. They shift into a protective repair-focused mode. They slow down growth, wrap up cellular cleanup processes, and become more resistant to damage. Cancer cells, on the other hand, are running on overdrive. Their growth signals are stuck in the on position because of the genetic mutations that drive cancer in the first place. That means when nutrients become scarce, cancer cells largely can't make that same protective switch. They keep trying to grow and divide right in the middle of a chemotherapy infusion designed to attack rapidly dividing cells. The result, at least in theory, is that fasting widens the gap between how healthy cells and cancer cells respond to treatment. Healthy cells get a temporary shield. Cancer cells stay exposed. That's the biological rationale researchers have been testing in actual patients. And that's what we'll see, the early results in several cancer types are lining up with this theory. Hey everybody, I want to take just a quick moment and invite you to my website drstengler.com. Here we have the supplements that we've been using with our patients for many many years. High quality and high potency supplements, very pure. So, if you're looking for high quality supplements where you can notice a difference both in how you feel and on your lab test, go to our website at drstengler.com. Now, how is this actually done in practice? Across the clinical trials, the approaches vary, but two main protocols show up again and again. The first is short-term water fasting. Most studies have patients begin fasting somewhere between 24 and 36 hours before their chemotherapy infusion and continue for about 24 hours afterward. So, total window of roughly 48 to 72 hours. A few trials have pushed this to 96 hours, though that's less common. During this time, water is almost always allowed. Staying hydrated is non-negotiable. Some protocols also allow black coffee and herbal teas, but for the most part, water's been used. The second approach is the fasting mimicking diet, also known as FMD. This isn't a true fast, it's a low calorie diet, around 600 calories a day, built around plant-based soups, crackers, and herbal teas designed to ease the body into a fasting-like state while easing some of the hunger. FMD typically starts 3 days before chemo and continues through the day of infusion. Also, it's important to note this type of approach is not for everyone. If you're underweight, malnourished, have uncontrolled diabetes, other certain medical conditions, you've got to work with an integrative doctor to make sure this is right for you. So, what does the evidence actually show? The most influential study so far is known as the DIRECT trial, a multi-center randomized phase two study out of the Netherlands, published in Nature Communications. Researchers enrolled 131 women with early-stage breast cancer and randomly assigned them to either follow the fasting mimicking diet or eat normally before each round of chemotherapy given ahead of surgery. The results were notable. Women on the fasting mimicking diet were significantly more likely to have their tumor shrink on imaging. And when surgeons examined the removed tumors afterward, the fasting group was nearly four times more likely have 90 to 100% of their tumor cells destroyed compared to the group that ate normally. The fasting group also showed less chemotherapy-related DNA damage in their immune cells, meaning their bodies' defenses came through treatment in better shape. And critically, there was no jump in serious side effects, even though the fasting group received less of the standard anti-nausea steroid. A follow-up randomized trial in 2024 showed that with 44 breast cancer patients across eight chemo cycles, they had really good results. The fasting-mimicking diet group had fewer cases of severe vomiting, fewer dangerously low white blood cell counts, better preserved red blood cells, lower levels of a growth hormone linked to cancer cell survival, and lower inflammation markers. Tumor response also favored the fasting group. But the study generating the most buzz right now came out of the 2026 American Society of Clinical Oncology meeting in Chicago and was published simultaneously in the Journal of Clinical Oncology. Led by Dr. Claudia Marchetti at a university hospital in Rome, this trial focused on 36 women with advanced high-grade ovarian cancer, one of the deadliest gynecological cancers and is responsible for roughly three quarters of ovarian cancer deaths in the United States. Patients were randomized to either fast for 36 hours before and 24 hours after each of the three pre-surgery chemo cycles with water allowed throughout or to eat their normal diet. The primary goal was insulin levels since insulin is known to fuel tumor growth. In the fasting group, insulin dropped. In the non-fasting group, it actually went up. But the bigger headline was tumor response. Nearly three in five patients in the fasting group had their cancer respond completely or almost completely before surgery, a substantially higher rate than the non-fasting group. And here's the part that really stands out. Patients in the fasting group went roughly three years on average before their cancer came back or progressed compared to about two years in the non-fasting group. Researchers also saw early signs that fasting changed immune cell activity in ways that might help the immune system fight the cancer more effectively. And side effects were no worse than in the control group. It was noted that this simple intervention has real benefits and can be put into practice almost everywhere. A larger multi-center trial is now being planned to confirm these findings. Beyond tumor shrinkage, there's another angle that matters just as much to patients, how they feel during treatment. A 2024 systematic review pooling seven randomized trials found that fasting patients had far fewer mouth sores, headaches, muscle weakness, digestive tract inflammation, diarrhea, vomiting, and nausea, and fewer treatment delays caused by side effects compared to patients eating normally. A separate review from the same year suggested fasting might also reduce damage to healthy DNA and ease fatigue, though the authors were careful to note that the results across studies are still mixed. The likely explanation ties back to that same metabolic shift. When insulin, blood sugar, and certain growth hormones drop during a fast, the body redirects energy away from the growth and toward maintenance and repair. Fasting also pushes by to burn fat for fuel and may favorably influence immune function. And there's a psychological piece, too. In multiple trials, patients reported feeling a greater sense of control over their own treatment, which translated into better emotional well-being scores. Now, a few important caveats. Most of these trials have been small, focused mainly on breast and gynecological cancers, and used different fasting lengths and outcome measures. So, it's too early to say this applies the same way across every cancer type. A 2023 systematic review looked at nine studies and nearly 380 patients found encouraging reductions in chemotherapy toxicity, but noted most of the underlying studies were only of low to moderate quality. But the good news is that bigger trials are underway, including a phase three study in the Netherlands enrolling 240 patients with hormone receptor positive breast cancer. So, the bottom line from oncology researchers right now is that short-term fasting around chemotherapy appears safe and feasible for most adults who aren't underweight, but it should always be done from the guidance of your cancer team and a nutritional professional. If you found this breakdown helpful, hit subscribe for more evidence-based deep dives into integrative cancer care and just general nutritional therapies. And let me know in the comments what questions you may have.

‍